At Viatris' request, US agency will review another Novo Nordisk patent on semaglutide

In Viatris' attempt to become the first company to reach the market with generic versions of Novo Nordisk’s diabetes and obesity juggernauts Ozempic and Wegovy, the company received good and bad news this week.